|Title:||Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles|
|Abstract:||Intermediate release nicotinic acid formulations having unique urinary metabolite profiles, which are suitable for oral administration once-a-day as a single dose during a 24 hour period for treating hyperlipidemia without causing drug-induced hepatotoxicity or drug-induced elevations in uric acid or glucose or both to levels that require the therapy to be discontinued, are disclosed.|
|Inventor(s):||Cefali; Eugenio A. (Lauderhill, FL)|
|Assignee:||Kos Pharmaceuticals, Inc. (Miami, FL)|
Patent Claim Types:|
see list of patent claims
|Use; Formulation; Compound; Dosage form;|
Back Citations: 2nd percentile
Forward Citations: 1st percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.